Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

CLSA Upgrades ResMed to Buy

CLSA analyst Andrew Paine upgrades ResMed (NYSE:RMD) from Outperform to Buy.

byBenzinga Newsdesk

January 13, 2022

1 minute read

CLSA analyst Andrew Paine upgrades ResMed (NYSE:RMD) from Outperform to Buy.

Credit Suisse Maintains Outperform on Vontier, Raises Price Target to $32

By Benzinga Newsdesk

Today, 7:59 AM

Credit Suisse analyst John Walsh maintains Vontier (NYSE:VNT) with a Outperform and raises the price target from $30 to $32.

VNT

Apple’s AR/VR Headset: Watch For These Updates At WWDC Next Week

By Shanthi Rexaline

Today, 7:59 AM

As Apple, Inc.'s (NASDAQ: AAPL) reality headset launch timeline polarizes people, Bloomberg columnist Mark Gurman has reiterated his view that neither the hardware nor the reality operating system would be announced at next week's annual Worldwide Developers Conference.

AAPL

Needham Maintains Buy on Lantronix, Lowers Price Target to $10

By Benzinga Newsdesk

Today, 7:59 AM

Needham analyst Ryan Koontz maintains Lantronix (NASDAQ:LTRX) with a Buy and lowers the price target from $12 to $10.

LTRX

News

Hibbett Says Giving Away 12 Months Of Kicks For Nike Air Max Month

By Benzinga Newsdesk

Today, 7:59 AM

Hibbett (NASDAQ:HIBB), a Birmingham-based premium footwear and athleisure retailer with more than 1,000 Hibbett Sports and City Gear specialty stores nationwide, today announced an Air Max Day inspired giveaway with

HIBB

CLSA Upgrades ResMed to Buy

Related Posts

Credit Suisse Maintains Outperform on Vontier, Raises Price Target to $32

Apple’s AR/VR Headset: Watch For These Updates At WWDC Next Week

Needham Maintains Buy on Lantronix, Lowers Price Target to $10

Hibbett Says Giving Away 12 Months Of Kicks For Nike Air Max Month